Status:

COMPLETED

Impact of Uterotonic Agents on Isolated Human Myometrium

Lead Sponsor:

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Conditions:

Postpartum Hemorrhage

Eligibility:

FEMALE

Phase:

NA

Brief Summary

The purpose of this study is to compare the ability of a sample of uterine muscle tissue to contract in the presence of various drugs. The drugs studied are typically used to contract the uterus when ...

Detailed Description

Postpartum hemorrhage (PPH) is a major cause of maternal mortality and morbidity. In 80% cases of PPH, the primary cause is failure of the uterus to contract after delivery of the baby, which then req...

Eligibility Criteria

Inclusion

  • Gestational age 37-41 weeks
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring primary Cesarean section
  • Cesarean section under spinal anesthesia

Exclusion

  • Patients who require general anesthesia
  • Patient who had previous uterine surgery or Cesarean section
  • Patients with placental anomalies
  • Emergency Cesarean section in labor
  • Patients with bleeding disorders

Key Trial Info

Start Date :

June 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT00989027

Start Date

June 1 2007

End Date

August 1 2013

Last Update

February 20 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mount Sinai Hospital

Toronto, Ontario, Canada, M5G 1X5

Impact of Uterotonic Agents on Isolated Human Myometrium | DecenTrialz